Compare Nasdaq Inc (NDAQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs BIO-TECHNE Corp — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Nasdaq Inc is far larger — about 4.7× BIO-TECHNE Corp's market cap, and Nasdaq Inc pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| NDAQ | TECH | |
|---|---|---|
Market Cap | $51.96B | $11.16B |
Sector | Financials | Health |
52-Week High | $100.98 | $72.12 |
52-Week Low | $76.85 | $43.31 |
Enterprise Value | $59.02B | $11.24B |
Dividend Yield | 1.22% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
